Optimizing the adeno-associated viral vector system: A brief summary

Therapeutic Delivery

Volumn 2, Issue 8, 2011, Pages 967-970

  Hacker, Ulrich ^a   Büning, Hildegard ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

adeno associated viral vectors; cell surface targeting; immune response; off target transduction; post transcriptional targeting

Indexed keywords

MICRORNA; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ADENOVIRUS 2; GENE EXPRESSION; GENETIC TRANSFECTION; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS RECOMBINANT;

EID: 80052406727     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.69     Document Type: Review

References (24)

1. Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19(1), 16-27 (2011).
2. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220-10225 (2010).
3. Burova E, Ioffe E. Chromatographic purifcation of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther. 12(Suppl. 1), S5-S17 (2005). (Pubitemid 41541749)
4. Pulicherla N, Asokan A. Peptide affnity reagents for AAV capsid recognition and purifcation. Gene Ther. DOI:10.1038/gt.2011.46 (2011) (Epub ahead of print).
5. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12(5), 341-355 (2011).
6. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 10(7), 717-733 (2008). (Pubitemid 352003915)
7. Derda R, Tang SK, Li SC et al. Diversity of phage-displayed libraries of peptides during panning and amplifcation. Molecules 16(2), 1776-1803 (2011).
8. Michelfelder S, Kohlschutter J, Skorupa A et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 4(4), e5122 (2009).
9. Ying Y, Muller OJ, Goehringer C et al. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17(8), 980-990 (2010).
10. Grimm D, Lee JS, Wang L et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (12), 5887-5911 (2008). (Pubitemid 351822263)
11. Koerber JT, Klimczak R, Jang JH et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 17 (12), 2088-2095 (2009).
12. Gray SJ, Blake BL, Criswell HE et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18(3), 570-578 (2010).
13. Li W, Zhang L, Johnson JS et al. Generation of novel A AV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17(12), 2067-2077 (2009).
14. Zhong L, Li B, Mah CS et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-effciency transduction at lower doses. Proc. Natl Acad. Sci. USA 105(22), 7827-7832 (2008). (Pubitemid 351872723)
15. Kern A, Schmidt K, Leder C et al. Identifcation of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77(20), 11072-11081 (2003). (Pubitemid 37204297)
16. Opie SR, Warrington KH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identifcation of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77(12), 6995-7006 (2003). (Pubitemid 36666892)
17. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adeno-associated virus type 2 contains an integrin a5b1 binding domain essential for viral cell entry. J. Virol. 80(18), 8961-8969 (2006). (Pubitemid 44359970)
18. Gruh I, Wunderlich S, Winkler M et al. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specifc expression from lentiviral vectors. J. Gene Med. 10 (1), 21-32 (2008).
19. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12(5), 329-40 (2011).
20. Geisler A, Jungmann A, Kurreck J et al. microRNA122-regulated transgene expression increases specifcity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 18(2), 199-209 (2011).
21. Qiao C, Yuan Z, Li J et al. Liver-specifc microRNA-122 target sequences incorporated in A AV vectors effciently inhibits transgene expression in the liver. Gene Ther. 18(4), 403-410 (2011).
22. Maersch S, Huber A, Buning H, Hallek M, Perabo L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 397(1), 167-175 (2010).
23. Halbert CL, Metzger MJ, Lam SL, Miller AD. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther. 18(4), 411-417 (2011).
24. Lu H, Qu G, Yang X, Xu R, Xiao W. Systemic elimination of de novo capsid protein synthesis from replication-competent A AV contamination in the liver. Hum. Gene Ther. 22(5), 625-632 (2011).